Abstract:
This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.
Abstract:
The subject invention provides novel Plasmodium falciparum antigens and novel polynucleotides encoding these antigens. Also provided by the subject invention are methods of using these antigens and polynucleotides.
Abstract:
This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare influenza virus epitopes, and to develop epitope-based vaccines directed towards influenza virus. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of influenza virus infection.
Abstract:
This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.
Abstract:
The present invention provides novel artificial oligopeptides capable of binding HLA Class II molecules encoded by several alleles. The oligopeptides include the sequence AX1FVAAX2TLX3AX4A (SEQ ID NO : 1), wherein X1 is selected from the group consisting of W, F, Y, H, D, E, N, Q, I and K; X2 is selected from the group consisting of F, N, Y and W; X3 is selected from the group consisting of H and K, and X4 is selected from the group consisting of A, D and E, with the proviso that the oligopeptide sequence is not AKFV AAWTLKAAA. The invention also relates to larger peptides comprising the oligopeptides, polynucleotides encoding the oligopeptides and larger peptides, as well as to compositions comprising the oligopeptides, peptides or polynucleotides. Also disclosed are methods for inducing immune responses.
Abstract:
The present invention provides novel artificial oligopeptides capable of binding HLA Class II molecules encoded by several alleles. The oligopeptides include the sequence AX 1 FVAAX 2 TLX 3 AX 4 A (SEQ ID NO : 1), wherein X 1 is selected from the group consisting of W, F, Y, H, D, E, N, Q, I and K; X 2 is selected from the group consisting of F, N, Y and W; X 3 is selected from the group consisting of H and K, and X 4 is selected from the group consisting of A, D and E, with the proviso that the oligopeptide sequence is not AKFV AAWTLKAAA. The invention also relates to larger peptides comprising the oligopeptides, polynucleotides encoding the oligopeptides and larger peptides, as well as to compositions comprising the oligopeptides, peptides or polynucleotides. Also disclosed are methods for inducing immune responses.
Abstract translation:本发明提供能够结合由几个等位基因编码的HLA II类分子的新型人造寡肽。 寡肽包括序列AX1FVAAX2TLX3AX4A(SEQ ID NO:1),其中X1选自W,F,Y,H,D,E,N,Q,I和K; X2选自F,N,Y和W; X 3选自H和K,X 4选自A,D和E,条件是寡肽序列不是AKFV AAWTLKAAA。 本发明还涉及包含寡肽的较大肽,编码寡肽的多核苷酸和较大肽,以及包含寡肽,肽或多核苷酸的组合物。 还公开了诱导免疫应答的方法。
Abstract:
The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen.
Abstract:
The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen.
Abstract:
This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.